NOVOB80

Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh · SET:NOVOB80

1.34 THB0.0100 +0.75%

Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh (SET:NOVOB80) last traded at 1.34 THB, up 0.75% on the day. Over the past year the stock is down 15.72%. Its 52-week range is 1.12 to 2.02. It is in the Health Technology sector (Pharmaceuticals: Major).

Key statistics

Open1.33

Day range1.33 – 1.36

52-week range1.12 – 2.02

Volume3.82 M

Average volume (10 days)2.63 M

Market cap (USD)175.64 B

P/E0.0101

EPS (TTM) (USD)3.99

Dividend yield4.40%

Beta (1 year)−0.4368

Revenue (TTM) (USD)50.21 B

Employees68.79 K

Performance

+2.29%1 week

+6.35%1 month

−14.65%3 months

−7.59%6 months

−21.18%Year to date

−15.72%1 year

Technical rating

Buy

Daily summary of 11 oscillators and 15 moving averages. See every indicator

Latest headlines

Weekly Recap: Wegovy scripts 265k+ and injunction denied in Eli Lilly ad suitTradingView · 02 Nov 2026
Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026

Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.